CLOs on the Move

Cedars-Sinai

www.cedars-sinai.org

 
Since its beginning in 1902` Cedars-Sinai has evolved to meet the healthcare needs of one of the most diverse regions in the nation` continually setting new standards for quality and innovation in patient care` research` teaching and community service. Today` Cedars-Sinai is widely known for its national leadership in transforming healthcare for the benefit of patients. Cedars-Sinai receives consistent recognition for our excellence. Our awards include; being named one of America`s Best Hospitals by U.S. News & World Report` receiving the National Research Corporation`s Consumer Choice Award 19 years in a row for providing the highest-quality medical care in Los ...
  • Number of Employees: 5K-10K
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details
Peter Braveman
Senior Vice President of Legal Affairs Profile
Terri Cammarano
Senior Vice President of Legal Affairs and General Counsel Profile

Similar Companies

VNA Health Care

VNA Health Care is a Hartford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IBC USA Conferences

IBC USA Conferences is a Westborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CliniQAl Consult Corporation

CliniQAl Consult Corporation is a North York, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Trans Life Ambulance

Trans Life Ambulance is a Van Nuys, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Enterin Inc.

Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.